Long-Term Effects of Metal-on-Metal Cobalt-Chromium-Containing Prostheses Used in Total Knee Arthroplasty on Hearing and Tinnitus

Ozan Ozdemir,1 Alican Baris,2 Abdurrahman Cagliyan,1 Ozgur Yigit1

1Department of Otorhinolaryngology/Head and Neck Surgery, University of Health Sciences Turkey, Istanbul Training and Research Hospital, Istanbul, Turkey
2Department of Orthopedics and Traumatology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, Istanbul, Turkey

Abstract

Objectives: We aimed to determine the long-term effects of metal-on-metal (MoM) cobalt (Co)-chromium-containing prostheses used in total knee arthroplasty (TKA) on hearing and tinnitus.

Methods: A total of 88 patients with the normal otoscopic examination and normal blood B12 levels, consisting of 44 patients who had been using MoM Co-chromium-containing total knee prosthesis for more than 5 years, and 44 non-implanted patients with similar demographic characteristics, were randomly selected and included in the study. Patients with previous ear surgery, chronic middle ear disease, or conductive hearing loss were excluded from the study. All participants were evaluated with pure-tone audiometry (PTA), distortion product otoacoustic emission (DPOAE), tinnitus handicap inventory (THI), and tinnitus reaction questionnaire (TRQ).

Results: The mean age of the 88 patients was 67.22±10.4 years. The mean age of 44 patients who underwent TKA at least 5 years ago was 72.89±7.18 years, 75% of these patients had bilateral prostheses, and the mean prosthesis duration was 11.00±5.08 years (range 5–25). The two groups were compared statistically using PTA, DPOAE, THI, and TRQ scores. When the patient groups with and without prostheses were compared in terms of hearing and tinnitus, we did not find a significant difference between the two groups (p>0.05).

Conclusion: In our study, we observed that the long-term use of MoM Co-chromium total knee prostheses did not have an ototoxic effect, contrary to what was believed. We also found that prolonged prosthesis duration or undergoing bilateral surgery did not worsen hearing and tinnitus.

Keywords: Arthroplasty, cobalt, hearing loss, ototoxicity, tinnitus

Cobalt (Co) is an essential trace element for humans and is in the structure of cobalamin (Cbl), the functional unit of Vitamin B12 necessary for mammals. The B12 content in food is very low. Its greatest abundance is in meat, fish, and milk products. Cbl acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase in humans. The most important disease known to be caused by B12 deficiency is pernicious anemia.1
Prostheses containing trace elements such as Co and chromium are used in many areas, especially in total knee arthroplasties (TKA) and total hip arthroplasties (THA). Metal-on-metal (MoM) prostheses are predominantly comprised of Co (64%) and chromium (Cr) (28%) and these prostheses corrode over time and can trigger systemic metallic ion release.\(^2\) Especially, some MoM TKA and THA configurations have been correlated with high Co and Cr levels, local adverse reactions, pseudotumors, vasculitis-associated lesions, systemic allergic reactions, hypersensitivity, and skin reactions.\(^3-6\)

Co overexposure has been shown to cause a variety of adverse health effects. Internal exposure through MoM orthopedic implants and oral intake of Co supplements deliver the highest systemic Co concentrations.\(^7\) In some cases, the increase in free ionic Co has been associated with a decrease in serum carrier proteins (90–95% binds with albumin) and monitoring of the Co\(^{2+}\) free fraction is recommended for future risk assessment. Renal failure, iron deficiency, sepsis, malnutrition, alcoholism, or drug intake may reduce Co-albumin binding, thereby increasing free Co\(^{2+}\) ions, resulting in toxic manifestations at low doses.\(^8\) Several factors can lead to higher metal ion levels: Suboptimal surgical positioning of the implant, different types of prosthesis, excessive number of modular connections, impaired kidney function, and bilateral implantation.\(^6,9\)

High blood Co levels are mainly associated with neurological, cardiovascular, and endocrine problems. These systemic effects have been expressed as the “arthroprosthetic cobaltism” syndrome.\(^10\) There are a variety of symptoms related to hearing and balance, vision, cognitive function, and sensory-motor performance. Furthermore, these symptoms often coincide with polyneuropathy.\(^10-13\) Hearing loss is always sensorineural and usually progressive. Furthermore, hearing impairment is mostly bilateral and more severe at higher frequencies. In addition, patients may complain about tinnitus and vertigo.

Exposure to Co can cause increased oxidative stress and DNA damage induced by free radicals.\(^14\) The ototoxic effects of Co are due to the production of reactive oxygen species and its effect on basal outer hair cells.\(^15\) Loss of hair cells in the cochlea usually presents as sensorineural hearing loss and tinnitus.

The main hypothesis of this study was to examine the ototoxic effects of MoM Co-chromium-containing prostheses used in TKA on hearing and tinnitus.

**Methods**

**Ethical Approval**

The study was approved by the Local Ethics Committee (No.2906/13.08.2021). All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional and National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. There were no animals involved in this study.

**Patients and Study Design**

A total of 88 patients with normal otoscopic examination and blood B12 levels, similar body mass index (BMI; kg/m\(^2\)), ethnicity, and age were included in this study. All patients were evaluated by otomicroscopic examination. Patients with the previous ear surgery, chronic middle ear disease, or conductive hearing loss were excluded from the study. The patients were divided into two groups as patients with total knee replacement for more than 5 years (range 5–25) and the control group. All implanted 44 patients were operated under spinal anesthesia by a single-experienced surgeon using the same technique and surgical instruments. Anteroposterior and lateral control knee radiographs were taken before hearing and tinnitus evaluations of all patients with prostheses (Fig. 1).

Forty-four patients in the control group were randomly selected from patients of similar age and comorbid disease history, who presented to our ear, nose, and throat outpatient clinic with complaints other than hearing loss and tinnitus. All 88 patients were evaluated with pure-tone audiometry (PTA) test, otoacoustic emission test (OAE), tinnitus handicap inventory (THI), and tinnitus reaction question-
naire (TRQ). Hearing levels and tinnitus scores of the two groups were compared.

When calculating the prosthesis duration of patients with bilateral prostheses, prosthesis durations were added. For example, the prosthesis period of a patient who had the first prosthesis surgery 7 years and the second prosthesis surgery 3 years ago was evaluated as 10 years.

**Surgical Technique**

All patients were operated by a single-experienced orthopedic specialists in our institute. The procedure was performed with the patient in supine position under spinal anesthesia. All patients received a primary cemented cruciate retaining implants (Vanguard Complete Knee System; Zimmer, Biomet, Indiana, USA) using the standard medial parapatellar approach. Soft-tissue releases were performed if needed. The patella was not resurfaced. A tourniquet was used to control bleeding during the surgery and a drain was placed to monitor post-operative bleeding.

**Patient Evaluation**

Forty-four patients who had been using MoM total knee prostheses for at least 5 years were included in the study. After otomicroscopy, PTA and distortion product otoacoustic emission (DPOAE) measurements of prosthesis patients without chronic ear disease were performed. After these measurements, patients filled out THI and TRQ, and tinnitus scores were recorded. As the control group, 44 patients without prosthesis, who presented to the otolaryngology outpatient clinic with a complaint other than tinnitus, had normal otomicroscopy, had similar demographic and comorbid characteristics, and were randomly selected. These two groups, consisting of equal numbers of patients, were compared with each other in terms of PTA, DPOAE, THI, and TRQ.

**Statistical Analysis**

In the data obtained from the study of Leyssens et al. using the G Power 3.1.9.7 (Franz Faul, Germany) program, “The ototoxic potential of cobalt from metal-on-metal hip implants: a pilot study on the patient-reported auditory, vestibular, and general neurological outcome,” the effect size is assumed to be d: 0.397. In the calculations for the determining effect size, 95% power, 10% margin of error, and one-way statistical significance, it was determined that there should be a total of at least 88 samples.

Statistical analysis was performed using the IBM SPSS Statistics 23.0 package program (SPSS Corp; Armonk, NY, USA). Kolmogorov–Smirnov test was used to determine whether the variables were normally distributed. Descriptive statistics of the data are presented with n (%) and normal distributions are shown as mean±SD. The Mann–Whitney U-test was used when evaluating non-parametric variables between the two groups. The benferroni multiple comparison test was used while investigating the reason for the significant difference between the groups. Analysis of categorical variables was carried out with the Chi-square (Exact) Test. Spearman correlation test was used to evaluate the relationships between quantitative variables. P<0.05 was considered statistically significant.

**Results**

A total of 88 patients, 61 male and 27 male, were included in the study. The mean age of the participants was 67.22±12.23 years (range 32–86). Of the 88 people participating in the study, 51 (57.95%) had hypertension and 19 (21.59%) had diabetes mellitus. About 75% of the patients had bilateral prostheses and the mean prosthesis time was 11.00±5.08 years (range 5–25) (Table 1).

Participants with and without prostheses were compared in terms of PTA test, tinnitus handicap index, and TRQ.

| Table 1. Demographic characteristics of the patients |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Gender                          | MoM patients                   | Control subjects               |
|                                 | n     | %    | n     | %    |
| Female                          | 41    | 93.18| 20    | 45.45|
| Male                            | 3     | 6.82 | 24    | 54.55|
| Age (mean±SD)                   | 72.89±7.18 |       | 61.55±13.62 |
| Comorbidity                     |       |      |       |      |
| Hypertension                    | 18    | 40.90| 13    | 29.55|
| Diabetes                        | 9     | 20.45| 7     | 15.90|
| BMI (mean±SD)                   | 27.79±6.29 |       | 28.20±3.34 |

MoM: Metal-on-metal; BMI: body mass index; SD: standard deviation.
There was no statistically significant difference between the two groups (p>0.05, Table 2). In addition, both groups were compared in terms of 1k, 2k, 4k, 6k, and 8k Hertz DP-OAE measurements, and similar results were obtained (p>0.05, Table 3).

In the prosthesis group, patients were compared in terms of PTA test, tinnitus handicap index, and TRQ, depending on whether they had prosthesis on one or both sides. However, no statistically significant difference was found between them (p>0.05, Table 4). When the patients were compared in terms of 1k, 2k, 4k, 6k, and 8k Hertz DP-OAE measurements depending on whether they had prosthesis on one or both sides, no statistically significant correlation was found (p>0.05, Table 5).

There was no statistically significant relationship between prosthesis duration and PTA test, tinnitus handicap index, and TRQ (p>0.05, Table 6). In addition, there was no statistical difference between prosthesis duration and DP-OAE scores (p>0.05, Table 7).

**Discussion**

Co is an essential trace element for humans and is in the structure of Cbl, the functional unit of Vitamin B12 necessary for mammals. Cbl is a cofactor of the enzymes methylmalonyl-Coenzyme A mutase and methionine synthase, and specific proteins are involved in all steps of Cbl transport (such as intrinsic factor and haptocorrin). In Vitamin B12 deficiency, clinics such as methylmalonic aciduria, hyperhomocysteinemia, megaloblastic anemia, and Cbl neuropathy may occur. Deficiency is rare in people fed with meat, fish, and milk products, and Vitamin B12 deficiency was not detected in our study patients.

Knee replacement surgery is one of the most common procedures for knee osteoarthritis. Since the mid-1990s, the Co and Cr metal ions were observed, mostly due to wear caused by malpositioned components. Although wear in the TKA consists mainly of polyethylene debris, recent studies have demonstrated that abrasive and corrosive damage can occur in the femoral component of total knee replacements. Abrasive damage to the surface of the femoral component, inflammatory cell-induced corrosion, and mechanically assisted crevice corrosion can cause the release of metal ions from the implant bulk. Cadosch et al. showed that metal ions are able to induce the expression of different chemotactic cytokines in macrophages and osteoclasts, which may ultimately stimulate periprosthetic osteolysis and implant loosening. However, when we evaluated our patients with direct anteroposterior and lateral knee radiographs in our study, we did not see periprosthetic osteolysis.

Today, apart from diet and occupational exposure, the most common cause of Co elevation is MoM implants. Various studies show that Co levels will peak in the first 12 months postoperatively, after which the ion concentration will decrease to a steady-state. Lons et al. found significantly higher blood Co and Cr levels 1 year after TKA, consistent with the literature. Although elevated serum Co has been detected, particularly in the 1st year after MoM implants, the existing literature shows conflicting evidence of a dose-response relationship between Co level and systemic toxicity. Therefore, objective auditory outcome tests were preferred in our study.

**Table 2.** PTA, THI, and TRQ comparison of groups with and without prosthesis

|                        | MoM patients (n=44) | Control subjects (n=44) | p   |
|------------------------|---------------------|-------------------------|-----|
|                        | Mean±SD | Median | Mean±SD | Median |     |
| PTA 500 Herzt R (dB)   | 18.07±14.68 | 15.00 | 20.34±15.30 | 20.00 | 0.455 |
| PTA 1000 Herzt R (dB)  | 21.02±16.76 | 20.00 | 21.36±17.76 | 22.50 | 0.983 |
| PTA 2000 Herzt R (dB)  | 31.02±16.66 | 30.00 | 28.75±21.27 | 30.00 | 0.578 |
| PTA 4000 Herzt R (dB)  | 33.86±16.35 | 35.00 | 34.20±22.90 | 32.50 | 0.936 |
| PTA 500 Herzt L (dB)   | 18.30±14.18 | 15.00 | 20.11±17.24 | 20.00 | 0.782 |
| PTA 1000 Herzt L (dB)  | 21.14±15.77 | 20.00 | 22.05±18.81 | 20.00 | 0.916 |
| PTA 2000 Herzt L (dB)  | 29.09±16.22 | 27.50 | 29.55±21.21 | 30.00 | 0.910 |
| PTA 4000 Herzt L (dB)  | 33.30±17.39 | 35.00 | 36.25±22.36 | 40.00 | 0.491 |
| Tinnitus Handicap Inventory | 9.09±10.62 | 5.50 | 8.48±7.89 | 8.00 | 0.938 |
| Tinnitus Reaction Questionnaire | 12.25±14.90 | 7.50 | 12.70±11.08 | 15.00 | 0.560 |

MoM: Metal-on-metal; PTA: Pure-tone audiometry; THI: Tinnitus handicap inventory; TRQ: Tinnitus reaction questionnaire; R: Right; L: Left; dB: Desibel; SD: Standard deviation, independent two sample test.
Arthroprosthetic cobaltism is mainly associated with neurological, cardiovascular, and endocrine problems. Neurological symptoms are usually related to auditory and vestibular complaints (e.g., hearing loss, tinnitus, and imbalance). Gessner et al. detected these symptoms in 52% (13/25) of the cases in their study on patients with MoM hip implants. Ho et al. detected tinnitus in 26% (8/31) patients and hearing loss in 29% (9/31) patients with MoM hip implants. Although MoM Co-Cr total implant studies were generally performed on hip prostheses in the literature, we did not detect a significant difference in the study and control groups in terms of auditory and vestibular aspects in our study of total knee prostheses.

Li et al. in their experimental rat study to reveal the auditory damage of Co, they concluded that high-dose Co damaged outer hair cells more than inner hair cells, and the damage was more at the base of the cochlea. In our study, we used PTA and DPOAE measurements to objectively evaluate hair cell functions. In addition, we evaluated the neurological effects of Co with commonly used tests and did not detect a significant difference in tinnitus scores between the two groups.

The main limitation of the present study was that a limited number of patient populations were included in the study. Further studies with larger case numbers are needed. In addition, evaluation of patients with serum Co and Cr levels may increase the value of the study.

**Conclusion**

In our study, we found similar results in hearing and tinnitus evaluations in patient and control groups with similar demographic characteristics. From this, we can conclude that long-term or bilateral use of MoM Co-chromium-con-

| Table 3. DPOAE comparison of groups with and without prosthesis |
|---------------------------------------------------------------|
| **MoM patients (n=44)** | **Control subjects (n=44)** | **p** |
|------------------------|-----------------------------|-------|
|                        | **n** | **%** | **n** | **%** | **p** |
| 1k Herz DPOAE R        |       |       |       |       |       |
| −                      | 41    | 93.18 | 37    | 84.09 | 0.314 |
| +                      | 3     | 6.82  | 7     | 15.91 |       |
| 2k Herz DPOAE R        |       |       |       |       |       |
| −                      | 34    | 77.27 | 36    | 81.82 | 0.792 |
| +                      | 10    | 22.73 | 8     | 18.18 |       |
| 4k Herz DPOAE R        |       |       |       |       |       |
| −                      | 40    | 90.91 | 36    | 81.82 | 0.352 |
| +                      | 4     | 9.09  | 8     | 18.18 |       |
| 6k Herz DPOAE R        |       |       |       |       |       |
| −                      | 40    | 90.91 | 40    | 90.91 | 1.000 |
| +                      | 4     | 9.09  | 4     | 9.09  |       |
| 8k Herz DPOAE R        |       |       |       |       |       |
| −                      | 44    | 100.00| 41    | 93.18 | 0.241 |
| +                      | 0     | 0.00  | 3     | 6.82  |       |
| 1k Herz DPOAE L        |       |       |       |       |       |
| −                      | 39    | 88.64 | 35    | 79.55 | 0.383 |
| +                      | 5     | 11.36 | 9     | 20.45 |       |
| 2k Herz DPOAE L        |       |       |       |       |       |
| −                      | 35    | 79.55 | 35    | 79.55 | 1.000 |
| +                      | 9     | 20.45 | 9     | 20.45 |       |
| 4k Herz DPOAE L        |       |       |       |       |       |
| −                      | 37    | 84.09 | 37    | 84.09 | 1.000 |
| +                      | 7     | 15.91 | 7     | 15.91 |       |
| 6k Herz DPOAE L        |       |       |       |       |       |
| −                      | 43    | 97.73 | 40    | 90.91 | 0.360 |
| +                      | 1     | 2.27  | 4     | 9.09  |       |
| 8k Herz DPOAE L        |       |       |       |       |       |
| −                      | 44    | 100.00| 42    | 95.45 | 0.494 |
| +                      | 0     | 0.00  | 2     | 4.55  |       |

MoM: Metal-on-metal; DPOAE: Distortion product otoacoustic emission; R: Right; L: Left.
Table 4. PTA, THI, and TRQ comparison of unilateral and bilateral prosthesis surgery groups

|                      | Unilateral (n=11) prosthesis | Bilateral (n=33) prosthesis | p     |
|----------------------|------------------------------|-----------------------------|-------|
|                      | Mean±SD    | Median | Mean±SD    | Median |       |
| PTA 500 Herzt R (dB) | 15.00±12.65 | 15.00  | 19.09±15.33 | 15.00  | 0.538 |
| PTA 1000 Herzt R (dB)| 17.73±16.49 | 20.00  | 22.12±16.96 | 20.00  | 0.437 |
| PTA 2000 Herzt R (dB)| 31.82±19.01 | 25.00  | 30.76±16.11 | 30.00  | 0.873 |
| PTA 4000 Herzt R (dB)| 36.36±18.99 | 35.00  | 33.03±15.61 | 30.00  | 0.470 |
| PTA 500 Herzt L (dB) | 18.18±17.79 | 15.00  | 18.33±13.09 | 15.00  | 0.728 |
| PTA 1000 Herzt L (dB)| 20.91±18.00 | 20.00  | 21.21±15.26 | 20.00  | 0.810 |
| PTA 2000 Herzt L (dB)| 33.18±19.27 | 30.00  | 27.73±15.16 | 25.00  | 0.376 |
| PTA 4000 Herzt L (dB)| 38.18±20.77 | 40.00  | 31.67±16.14 | 30.00  | 0.283 |
| Tinnitus handicap inventory | 7.64±9.49 | 5.00   | 9.58±11.06 | 8.00   | 0.810 |
| Tinnitus reaction questionnaire | 11.73±13.81 | 7.00 | 12.42±15.45 | 8.00 | 0.979 |

PTA: Pure-tone audiometry; THI: Tinnitus handicap inventory; TRQ: Tinnitus reaction questionnaire; R: Right; L: Left; dB: decibel; SD: standard deviation.

Table 5. DPOAE comparison of unilateral and bilateral prosthesis surgery groups

|                      | Unilateral (n=11) prosthesis | Bilateral (n=33) prosthesis | p     |
|----------------------|------------------------------|-----------------------------|-------|
|                      | n  | %  | n  | %  |       |
| 1k Herzt DPOAE R     | 9  | 81.82 | 32 | 96.97 | 0.150 |
| –                    | 2  | 18.18 | 1  | 3.03  |       |
| +                    | 8  | 72.73 | 26 | 78.79 | 0.692 |
| 2k Herzt DPOAE R     | 0  | 0.00  | 4  | 12.12 |       |
| –                    | 11 | 100.00 | 29 | 87.88 | 0.558 |
| +                    | 3  | 27.27 | 7  | 21.21 |       |
| 4k Herzt DPOAE R     | 10 | 90.91 | 30 | 90.91 | 1.000 |
| –                    | 9  | 81.82 | 28 | 84.85 | 1.000 |
| +                    | 2  | 18.18 | 2  | 15.15 |       |
| 6k Herzt DPOAE R     | 11 | 100.00 | 33 | 100.00 |       |
| –                    | 0  | 0.00  | 0  | 0.00  |       |
| +                    | 0  | 0.00  | 0  | 0.00  |       |
| 8k Herzt DPOAE R     | 11 | 100.00 | 32 | 96.97 | 1.000 |
| –                    | 0  | 0.00  | 1  | 3.03  |       |
| +                    | 0  | 0.00  | 0  | 0.00  |       |

DPOAE: Distortion product otoacoustic emission; R: Right; L: Left.
taining prostheses does not have an ototoxic effect. However, the increased Co effect revealed in some studies may be due to conditions that decrease Co-albumin binding, such as renal failure, iron deficiency, sepsis, malnutrition, alcoholism, or drug intake.

### Table 6. Relationship between PTA, THI, TRQ, and prosthesis duration

| Prosthesis duration (years) | PTA 500 Hz. R | PTA 1000 Hz. R | PTA 2000 Hz. R | PTA 4000 Hz. R | PTA 500 Hz. L | PTA 1000 Hz. L | PTA 2000 Hz. L | PTA 4000 Hz. L | THI | TRQ |
|----------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|-----|-----|
| 1k Herzt DPOAE R           |               |               |               |               |               |               |               |               |     |     |
| −                          | 11.10±5.18    | 10.00         |               |               | 0.792         |               |               |               |     |     |
| +                          | 9.67±4.16     | 11.00         |               |               |               |               |               |               |     |     |
| 2k Herzt DPOAE R           |               |               |               |               |               |               |               |               |     |     |
| −                          | 11.06±5.34    | 10.00         |               |               | 0.901         |               |               |               |     |     |
| +                          | 10.80±4.37    | 11.00         |               |               |               |               |               |               |     |     |
| 4k Herzt DPOAE R           |               |               |               |               |               |               |               |               |     |     |
| −                          | 11.10±5.30    | 10.00         |               |               | 0.984         |               |               |               |     |     |
| +                          | 10.00±2.16    | 10.50         |               |               |               |               |               |               |     |     |
| 6k Herzt DPOAE R           |               |               |               |               |               |               |               |               |     |     |
| −                          | 11.30±5.18    | 10.50         |               |               | 0.165         |               |               |               |     |     |
| +                          | 8.00±2.94     | 8.00          |               |               |               |               |               |               |     |     |
| 8k Herzt DPOAE R           |               |               |               |               |               |               |               |               |     |     |
| −                          | 11.00±5.09    | 10.00         |               |               | −             |               |               |               |     |     |
| +                          | −             | −             |               |               |               |               |               |               |     |     |
| 1k Herzt DPOAE L           |               |               |               |               |               |               |               |               |     |     |
| −                          | 11.21±5.27    | 10.00         |               |               | 0.667         |               |               |               |     |     |
| +                          | 9.40±3.29     | 11.00         |               |               |               |               |               |               |     |     |
| 2k Herzt DPOAE L           |               |               |               |               |               |               |               |               |     |     |
| −                          | 10.57±5.01    | 10.00         |               |               | 0.156         |               |               |               |     |     |
| +                          | 12.67±5.32    | 12.00         |               |               |               |               |               |               |     |     |
| 4k Herzt DPOAE L           |               |               |               |               |               |               |               |               |     |     |
| −                          | 11.38±5.36    | 10.00         |               |               | 0.377         |               |               |               |     |     |
| +                          | 9.00±2.71     | 10.00         |               |               |               |               |               |               |     |     |
| 6k Herzt DPOAE L           |               |               |               |               |               |               |               |               |     |     |
| −                          | 10.95±5.14    | 10.00         |               |               | 0.545         |               |               |               |     |     |
| +                          | 13.00±0.00    | 13.00         |               |               |               |               |               |               |     |     |
| 8k Herzt DPOAE L           |               |               |               |               |               |               |               |               |     |     |
| −                          | 11.00±5.09    | 10.00         |               |               | −             |               |               |               |     |     |
| +                          | −             | −             |               |               |               |               |               |               |     |     |

PTA: Pure tone audiometry; THI: Tinnitus handicap inventory; TRQ: Tinnitus reaction questionnaire; R: Right; L: Left; Hz: Hertz.

### Disclosures

**Ethics Committee Approval:** The study was approved by the Local Ethics Committee (No.2906/13.08.2021).

**Peer-review:** Externally peer-reviewed.

**Funding:** There was no funding from either public, private, or third sector sources.

**Conflict of Interest:** The authors declare that they have no conflicts of interest.

### Authorship Contributions

Concept – O.O., O.Y.; Design – O.O., O.Y.; Supervision – O.O., O.Y.; Data collection &/or processing – O.O., A.B., A.C., O.Y.; Analysis and/or interpretation – O.O., A.B., A.C., O.Y. Literature search – O.O., A.B., A.C.; Writing – O.O., A.B., A.C.; Critical review – O.O., A.B., A.C., O.Y.

### References

1. Yamada K. Cobalt: its role in health and disease. Met Ions Life Sci 2013;13:295–320.
2. Jacobs JJ, Gilbert JL, Urban RM. Corrosion of metal orthopaedic implants. J Bone Joint Surg Am 1998;80:268–82.
3. Friesenbichler J, Sadoghi P, Maurer-Ertl W, Szkandera J, Glehr M, Ogris K, et al. Serum metal ion concentrations in paediatric patients following total knee arthroplasty using megaprostheses. Biomed Res Int 2014;2014:817257.
4. Sutphen SA, MacLaughlin LH, Madsen AA, Russell JH, McShane MA. Prevalence of pseudotumor in patients after metal-on-metal hip arthroplasty evaluated with metal ion analysis and MARS-MRI. J Arthroplasty 2016;31:260–3.
5. Mahendra G, Pandit H, Kliskey K, Murray D, Gill HS, Athanasou N. Necrotic and inflammatory changes in metal-on-metal resurfacing hip arthroplasties. Acta Orthop 2009;80:653–9.
6. Vendittoli PA, Amzica T, Roy AG, Lusignan D, Girard J, Lavigne M. Metal ion release with large-diameter metal-on-metal hip arthroplasty. J Arthroplasty 2011;26:282–8.
7. Leyssens L, Vinck B, Van Der Straeten C, Wuyts F, Maes L. Cobalt toxicity in humans-A review of the potential sources and systemic health effects. Toxicology 2017;387:43–56.
8. Paustenbach DJ, Tvermoes BE, Unice KM, Finley BL, Kerger BD. A review of the health hazards posed by cobalt. Crit Rev Toxicol 2013;43:316–62.
ions after resurfacing arthroplasty of the hip. J Bone Joint Surg Br 2008;90:1143–51.

10. Tower SS. Arthroprosthetic cobaltism: neurological and cardiac manifestations in two patients with metal-on-metal arthroplasty: a case report. J Bone Joint Surg Am 2010;92:2847–51.

11. Oldenburg M, Wegner R, Baur X. Severe cobalt intoxication due to prosthesis wear in repeated total hip arthroplasty. J Arthroplasty 2009;24:825.e15–20.

12. Mao X, Wong AA, Crawford RW. Cobalt toxicity—an emerging clinical problem in patients with metal-on-metal hip prostheses? Med J Aust 2011;194:649–51.

13. Pazzaglia UE, Apostoli P, Congiu T, Catalani S, Marchese M, Zarrattini G. Cobalt, chromium and molybdenum ions kinetics in the human body: data gained from a total hip replacement with massive third body wear of the head and neuropathy by cobalt intoxication. Arch Orthop Trauma Surg 2011;131:1299–308.

14. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1–40.

15. Zou W, Yan M, Xu W, Huo H, Sun L, Zheng Z, et al. Cobalt chloride induces PC12 cells apoptosis through reactive oxygen species and accompanied by AP-1 activation. J Neurosci Res 2001;64:646–53.

16. Osman D, Cooke A, Young TR, Deery E, Robinson NJ, Warren MJ. The requirement for cobalt in vitamin B12: A paradigm for protein metalation. Biochim Biophys Acta Mol Cell Res 2021;1868:118896.

17. Talmaç MA, Görgel MA, Birsel SE, Sönmez MM, Özdemir HM. The effect of single high-dose preoperative intravenous tranexamic acid administration to reduce blood loss in patients with primary total knee replacement. Sisli Etfal Hastan Tip Bul 2019;53:137–42.

18. Hart AJ, Quinn PD, Sampson B, Sandison A, Atkinson KD, Skinner JA, et al. The chemical form of metallic debris in tissues surrounding metal-on-metal hips with unexplained failure. Acta Biomater 2010;6:4439–46.

19. Arnhold CM, MacDonald DW, Malkani AL, Klein GR, Rimnac CM, Kurtz SM; et al. Corrosion damage and wear mechanisms in long-term retrieved CoCr femoral components for total knee arthroplasty. J Arthroplasty 2016;31:2900–6.

20. Gilbert JL, Sivan S, Liu Y, Kocagöz SB, Arnhold CM, Kurtz SM. Direct in vivo inflammatory cell-induced corrosion of CoCrMo alloy orthopedic implant surfaces. J Biomed Mater Res A 2015;103:211–23.

21. Cadosch D, Gautschi OP, Chan E, Simmen HP, Filgueira L. Titanium induced production of chemokines CCL17/TARC and CCL22/MDC in human osteoclasts and osteoblasts. J Biomed Mater Res A 2010;92:475–83.

22. Tvermoes BE, Paustenbach DJ, Kerger BD, Finley BL, Unice KM. Review of cobalt toxicokinetics following oral dosing: Implications for health risk assessments and metal-on-metal hip implant patients. Crit Rev Toxicol 2015;45:367–87.

23. Heisel C, Streich N, Krachler M, Jakubowtiz E, Kretzer JP. Characterization of the running-in period in total hip resurfacing arthroplasty: an in vivo and in vitro metal ion analysis. J Bone Joint Surg Am 2008;90 Suppl 3:125–33.

24. Haddad FS, Thakrar RR, Hart AJ, Skinner JA, Nargol AV, Nolan JF, et al. Metal-on-metal bearings: the evidence so far. J Bone Joint Surg Br 2011;93:572–9.

25. Lons A, Putman S, Pasquier G, Migaud H, Drumez E, Girard J. Metallic ion release after knee prosthesis implantation: a prospective study. Int Orthop 2017;41:2503–8.

26. Gessner BD, Steck T, Woelber E, Tower SS. A systematic review of systemic cobaltism after wear or corrosion of chrome-cobalt hip implants. J Patient Saf 2019;15:97–104.

27. Ho JH, Leikin JB, Dargan PI, Archer JRH, Wood DM, Brent J. Metal-on-metal hip joint prostheses: a retrospective case series investigating the association of systemic toxicity with serum cobalt and chromium concentrations. J Med Toxicol 2017;13:321–8.

28. Jelsma J, Schotanus M, Kleinveld H, Grimm B, Heyligers I. Self-reported systemic complaints in patients with metal-on-metal hip arthroplasty. J Orthop 2020;18:213–7.

29. Leyssens L, Vinck B, Van Der Straeten C, De Smet K, Dhooge I, Wuysts FL, et al. The ototoxic potential of cobalt from metal-on-metal hip implants: objective auditory and vestibular outcome. Ear Hear 2020;41:217–30.

30. Li P, Ding D, Salvi R, Roth JA. Cobalt-induced ototoxicity in rat postnatal cochlear organotypic cultures. Neurotox Res 2015;28:209–21.